Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine
Phase 2UNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
Oct 11, 2019 → Aug 31, 2022
NCT ID
NCT04097444About Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine is a phase 2 stage product being developed by Chugai Pharmaceutical for Metastatic Colorectal Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04097444. Target conditions include Metastatic Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04097444 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Metastatic Colorectal Cancer